ipilimumab
bms
['melanoma']
the question is no longer whether to use tils in metastatic melanoma, but rather when to do it, taking into account tox profile + time &amp; infrastructure tils require to be produced.
terrific academic trial presented by , discussed by ignacio molero. #esmo22 
MD (Oncology registrar) & Researcher @Hopitaux_unige (Geneva,CH) •PhD (@Cambridge_Uni) •MPH @LSHTM